Leukemia Research
Volume 28, Issue 12 , Pages 1347-1350 , December 2004

Treatment of acute promyelocytic leukemia in the very elderly: case report and review of the literature

  • Ronald L. Sham

      Affiliations

    • Hematology/Oncology Unit, Rochester General Hospital, 1425 Portland Ave., Rochester, NY 14621, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 585 922 4020; fax: +1 585 922 4622.
    • ,
  • Martin S. Tallman

      Affiliations

    • Division of Hematology/Oncology, Northwestern University Medical School, NMFF 676 N St. Clair Street, Suite 850, Chicago, IL 60611-6189, USA

Received 20 February 2004 ,Accepted 5 April 2004.

References 

  1. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759–767
  2. Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, et al.  A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J. Clin. Oncol. 1985;3:793–798
  3. Tallman M, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992;79:543–553
  4. Rowley JD, Golomb HM, Dogherty C. 15/17 Translocation: a consistent chromosomal change in acute promyelocytic leukemia. Lancet. 1977;1:549–550
  5. DeThe H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 1990;347:558–561
  6. Haung ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al.  Use of all trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572
  7. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L, et al.  All trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood. 1990;76:1704–1709
  8. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Eng. J. Med. 1998;339:1341–1348
  9. Lowenberg B. Managing therapy in older adult patients with acute myeloid leukemia. Semin. Hematol. 2001;38:10–16
  10. Sham RL. Successful management of an octogenarian with acute promyelocytic leukemia using all trans-retinoic acid. Am. J. Hematol. 1995;49:263–265
  11. Sham RL. Acute promyelocytic leukemia-from the bench to the bedside. Leuk. Res. 1997;21:295–297
  12. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al.  Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial: European APL 91 Group. Blood. 1993;82:3241–3249
  13. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al.  A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance in newly diagnosed acute promyelocytic leukemia. Eur. APL Group Blood. 1999;94:1192–1200
  14. Burnett AK, Grimwade D, Solomon E, Wheatly K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all trans-retinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131–4143
  15. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka E, et al.  Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all trans-retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J. Clin. Oncol. 1998;16:78–85
  16. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, et al.  A modified AIDA protocol with anthracycline-based consolidation results in a high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-alpha-positive acute promyelocytic leukemia. Blood. 1997;94:3015–3021
  17. Latagliata R, Avvisati G, Lo Coco F. The role of all trans-retinoic acid (ATRA) in newly diagnosed acute promyelocytic leukemia patients aged >60 years. Ann. Oncol. 1997;8:1273–1275
  18. Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, et al.  Treatment of elderly patients (> or = 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003;17(6):1085–1090
  19. Girmenia C, LoCoco F, Breccia M, Latagliata R, Spadea A, D’Andrea M, et al.  Infectious complications in patients with acute promyelocytic leukemia treated with the AIDA regimen. Leukemia. 2003;17(5):925–930
  20. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Semin. Hematol. 2001;38:26–36
  21. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al.  Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): II Clinical efficacy and the pharmacokinetics in relapsed patients. Blood. 1997;89:3354–3360
  22. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 Newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;10:3315–3324
  23. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am. J. Hematol. 2002;70:292–299

PII: S0145-2126(04)00177-8

doi: 10.1016/j.leukres.2004.04.009

Leukemia Research
Volume 28, Issue 12 , Pages 1347-1350 , December 2004

Article Tools